C60 (Buckminsterfullerene)

C60 (Buckminsterfullerene) carries a benign-to-moderate safety profile in practice: documented human harm is minimal, and the real limiter is weak efficacy rather than danger. The most cited concern is light-induced degradation of oil-solubilized C60, which one animal study linked to organ damage and reduced lifespan Shytikov 2021, but that is a product-quality and handling problem, not an intrinsic toxicity of properly stored C60. The European SCCS opinion notes that genotoxic potential of fullerene molecules cannot be fully excluded, which is a general-class theoretical gap rather than a demonstrated signal SCCS 2023. Human pharmacokinetic data are absent and no Phase I trial has been published, so cautious individuals, pregnant people, and those with existing conditions should still wait for better data, but the downside is mild.

Safety (Low): C60 has no demonstrated intrinsic catastrophic mechanism, so the SM-019 floor does not fire, but C60 sits above the benign band for two documented reasons. Its mechanism-level risks are narrow or extrinsic: the light-degraded C60-oil organ damage in mice is a storage and product-quality failure, and the SCCS 2023 inability to exclude fullerene genotoxicity is a class-level gap rather than a demonstrated event. On that mechanism score SM-074 then adds most of its allowed aggravator, because oral C60 has no human trial safety arm, no pharmacovigilance record and no documented long-term user population, alongside slow tissue retention.

Side effects (Low): C60 side effects reported in consumer communities are photosensitivity or easier sunburn, gastrointestinal distress on dose escalation, kidney-area discomfort, staining, and sleep or mood changes in either direction. That pattern matches the ladder band for common complaints, largely the gut cluster, in a meaningful minority and still self-limiting, with dose reduction, opaque refrigerated storage and discontinuation as workable controls. C60 does not reach the band above because no sourced incidence figure exists, and C60 is held off the floor because no systematic human surveillance exists either, which under SM-074 forbids reading missing data as demonstrated mildness.

Cost premium (Moderate): C60 is a genuine monthly burden with no cheaper legitimate route to the same exposure. Therapeutic-grade vacuum-baked or sublimated C60 oil runs 60 to 100 dollars a month at common anecdotal dosing, above the commodity-supplement range the band below covers. The 20 to 30 dollar industrial-grade products are not a cheaper equivalent route, because residual-solvent content, label concentration deviation and degradation make that exposure a different and unverified thing. Unlike a nutrient with a food route, C60 has no dietary or generic alternative delivering the same molecule, so the figure is a floor rather than a brand premium over something cheaper.

Effort (Low): C60 is operationally trivial to dose but carries standing handling discipline, which puts it just above the passive floor. Taking C60 is under two minutes: measure the oil, take it with a fat-containing meal, put it away. What lifts C60 off the floor is storage, because the product must stay refrigerated, opaque and light-protected continuously, and must be sourced with credible purity and residual-solvent documentation. Travel, a clear bottle, or a countertop left in daylight defeats the protocol, and the packet ties light degradation directly to the animal toxicity finding. The effort with C60 is vigilance rather than time.

Opportunity cost (Moderate): C60 sits in a crowded category where several better-validated options already dominate the same goals, which is the ladder's highest opportunity band rather than the milder one covering a single displacement risk. For oxidative stress, mitochondrial support and recovery the packet itself names astaxanthin, urolithin A, magnesium, creatine and omega-3 as cleaner choices carrying human endpoint data, and places C60 at the experimental end of a mature stack if anywhere. C60 also consumes supplement budget and attention directly. The measured corpus tendency is to score this dimension one band too low, which is corrected here.

Dependency (Negligible): C60 shows no dependency biology of any kind, placing it at the floor band. The packet records no withdrawal syndrome, no tolerance escalation, no addictive pharmacology and no rebound for C60, and no evidence that C60 downregulates endogenous antioxidant systems or creates a biological need to continue. Community reports describe either no effect or fading subjective benefit after stopping, which is the absence of a withdrawal picture rather than the presence of one. Slow tissue washout is a clearance property scored under reversibility, not a dependency, and benefit fading on stopping belongs to durability under the ladder's explicit carve-out.

Reversibility (Low): C60 does not wash out cleanly, which lifts it into the months-persistence band rather than the clean-clearance one. Rodent biodistribution shows C60 persisting in liver, spleen and adrenal tissue for extended periods, and the packet states plainly that no human washout pharmacokinetic study exists, so a user who stops C60 cannot confirm exposure has ended. This dimension measures how cleanly the intervention itself clears rather than whether benefit is retained, so the long retention is the relevant fact and the packet's functional-reversibility argument answers a different question. No permanent biological change from consumer dosing is documented, keeping C60 below the band above.